Clinical Trial: A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC

U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT07556549) titled 'A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC' on April 07.

Brief Summary: The purpose of this retrospective study is to learn about the real-world effects of the study medicine lorlatinib for the first-line treatment of Chinese adult patients who were diagnosed with ALK-positive a/mNSCLC.

The participants included in this study are:

* Aged 18 years or more

* diagnosed with a/mNSCLC

* confirmed with testing for ALK-positive

* have started first-line lorlatinib treatment during the patient selection period

In this study, the main objectives are to learn...